Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Nestlé    NESN   CH0038863350

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Nestle : Galderma Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis

share with twitter share with LinkedIn share with facebook
share via e-mail
11/01/2018 | 04:13pm CET

Lausanne - Galderma, Nestle Skin Health's medical solutions business, today announced positive results from a Phase 2b dose-ranging study of nemolizumab in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.

Nemolizumab, an investigational subcutaneous anti-IL-31 receptor A monoclonal antibody, met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline compared to placebo, and met secondary endpoints of major significance to Quality of Life improvement, such as Peak Pruritus Numerical Rating Scale (NRS) score vs. baseline for example.

'These clinical data, coupled with previous phase 2a results from our licensing partner Chugai, support the growing scientific evidence that the IL31 pathway may be an important driver in atopic dermatitis. These results clearly support dose selection and will allow us to pursue the development as planned. We confirm our intent to progress nemolizumab into phase 3 in 2019 ' said Thibaud Portal, Ph.D., Vice President of Galderma's Prescription business.

Atopic dermatitis is a chronic inflammatory skin disease, and is the most common form of eczema which frequently begins in childhood and can last through adulthood, although in some patients it may start in adulthood. Moderate-to-severe atopic dermatitis is characterized by an allergic response driven by a subset of immune cells called Type 2 helper T cells, or Th2 cells. IL-31, a cytokine released by Th2 cells, is involved in AD associated pruritus by interacting with IL-31 receptor alpha expressed by neurons, and is also thought to play a role in AD skin inflammation and AD skin barrier impairment. Moderate-to-severe forms of atopic dermatitis can be characterized by pronounced cutaneous dryness, and skin lesions marked by redness, infiltration/papulation, crusting/oozing, and lichenification, with periods of lesion exacerbation accompanied by intense itching, scratching, and skin damage that can lead to secondary infections. Moderate-to-severe atopic dermatitis can negatively impact patients' lives and is associated with a high burden to patients particularly with itching, sleep deprivation and depression.

About Nemolizumab

Nemolizumab, a humanized monoclonal antibody, is directed against the IL-31R alpha, which blocks IL-31 signaling. Nemolizumab, initially developed by Chugai, was subsequently licensed to Nestle Skin Health in 2016. Nemolizumab is an investigational agent under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.

About Galderma

Galderma, Nestle Skin Health's medical solutions business, was created in 1981 and is now present in over 100 countries with an extensive product portfolio to treat a range of dermatological conditions. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin.


Sebastien Cros

Email: info@nestleskinhealth.com

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NESTLÉ
11/13Nestle Purina Petcare Exploring French Plant Sale, Job Cuts -Reuters
11/13NESTLE : Purina PetCare mulls French plant sale, job cuts
11/13AIMMUNE THERAPEUTICS : Announces Additional Equity Investment by Nestle Health S..
11/13In Pet Sales, Food Faces Familiar Battle -- WSJ
11/12Nestle Raising Stake in Aimmune Therapeutics to 19% -- Update
11/12NESTLE : raises stake in food allergy drug developer Aimmune
11/12Nestle Raising Stake in Aimmune Therapeutics to 19%
11/12Big Food Encounters Familiar Challenges in Pet-Food Aisle
11/11Skipping breakfast may lead to obesity, study finds
11/09CORRECTION : Election 2018-House-Iowa-Steve King story
More news
News from SeekingAlpha
11/12How Long Can 'Big Beverage' Ignore A Company With 92% YoY Domestic Revenue Gr.. 
11/12Tracking Dan Loeb's Third Point Portfolio - Q3 2018 Update 
11/07First Eagle Global Value Team Quarterly Commentary Q3 2018 
11/07First Eagle Global Income Builder Fund Quarterly Commentary Q3 2018 
11/02Guardion Health Sciences Begins U.S. IPO Effort 
Financials (CHF)
Sales 2018 91 522 M
EBIT 2018 15 265 M
Net income 2018 11 276 M
Debt 2018 27 806 M
Yield 2018 2,94%
P/E ratio 2018 22,75
P/E ratio 2019 21,21
EV / Sales 2018 3,15x
EV / Sales 2019 3,05x
Capitalization 260 B
Duration : Period :
Nestlé Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NESTLÉ
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 87,1  CHF
Spread / Average Target 2,5%
EPS Revisions
Ulf Mark Schneider Chief Executive Officer & Director
Paul Bulcke Chairman
Magdi Batato Executive Vice President-Operations
François-Xavier Michel Marie Roger Chief Financial Officer & Executive Vice President
Stefan Palzer Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
NESTLÉ1.34%258 367